Myasthenia Gravis Market Treatment, Size, Share, Pipeline Review, H1 2016
Transcription
Myasthenia Gravis Market Treatment, Size, Share, Pipeline Review, H1 2016
Myasthenia Gravis Market Treatment, Size, Share, Pipeline Review, H1 2016: Radiant Insights Summary Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H1 2016', provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. Click for Report Details @ http://www.radiantinsights.com/research/myasthenia-gravis-pipelinereview-h1-2016 Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis - The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects - The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse More Market Research Reports @ http://www.radiantinsights.com/catalog/market-researchreports Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Myasthenia Gravis Overview 9 Therapeutics Development 10 Pipeline Products for Myasthenia Gravis - Overview 10 Pipeline Products for Myasthenia Gravis - Comparative Analysis 11 Myasthenia Gravis - Therapeutics under Development by Companies 12 Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 14 Myasthenia Gravis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Myasthenia Gravis - Products under Development by Companies 18 Myasthenia Gravis - Products under Investigation by Universities/Institutes 19 Myasthenia Gravis - Companies Involved in Therapeutics Development 20 Achillion Pharmaceuticals, Inc. 20 Akari Therapeutics, Plc 21 Alexion Pharmaceuticals, Inc. 22 arGEN-X BV 23 Baxalta Incorporated 24 Biokine Therapeutics Ltd. 25 BioMarin Pharmaceutical Inc. 26 CuraVac, Inc. 27 GlaxoSmithKline Plc 28 Grifols, S.A. 29 HanAll Biopharma Co., Ltd. 30 Click for Report Details @ http://www.radiantinsights.com/research/myasthenia-gravis-pipelinereview-h1-2016 About Us: Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036 San Francisco, CA 94105 United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Website: http://www.radiantinsights.com/ Email: [email protected] Visit our Blog: http://chemicalsandmaterialsri.blogspot.com/
Similar documents
Myasthenia Gravis Market Share, Size, Definition, Treatment, Pipeline Review, H2 2016
Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H2 2016', provides an overview of the Myasthenia Gravis pipeline landscape.
More information